**Test limitations and risks:** All risks and limitations outlined in the main Panorama consent form apply to the Panorama Microdeletion screening. See main Panorama consent form for details. In addition, the following limitations/risks apply:

- Panorama full microdeletion panel is NOT available for twin pregnancies or for pregnancies achieved using surrogate or egg donor.
- **If the mother is a known carrier for 22q11.2 deletion syndrome:** Panorama will not be able to return results on the fetus for 22q11.2 deletion syndrome. In this instance, it is recommended that you use another form of testing to detect the presence or absence of the 22q11.2 deletion in your fetus.
- **Risk of incidentally finding a maternal microdeletion:** This test screens for the 22q11.2 deletion in the fetus. However, it is possible during analysis that you may be identified to be at increased risk to be a carrier of a 22q11.2 deletion. If this occurs, the Panorama report will state that there is a 1 in 2 or 50% chance to have an affected pregnancy (as fetal status cannot be determined in this case). Because the Panorama test is not considered "diagnostic" for the mother of the fetus, your provider may offer additional testing to confirm if you carry the 22q11.2 deletion. In addition, finding out that you carry a microdeletion syndrome may cause feelings of anxiety or concern about your own health and well-being, as well as concerns about your pregnancy. Women who do not wish to risk finding out whether they carry this microdeletion should consider opting out of this screening test.
- If the percentage of fetal (placental) DNA in the sample is below 7%, screening for Angelman syndrome will not be performed and the results will be reported as "risk unchanged".

**Alternatives to Panorama Prenatal Microdeletion Syndrome Screening:** Maternal serum screening does not screen for microdeletion syndromes at this time. Other than the Panorama Microdeletion panel screen, you have the option of completing a diagnostic prenatal chromosome microarray on a CVS or amniocentesis sample. This will detect the above microdeletion syndromes, in addition to other microdeletions and microduplications that may be of clinical significance. You may also choose to have no prenatal screening or testing for microdeletion syndromes.

**PATIENT CONSENT STATEMENT:**

I have read or have had read to me the above consent addendum about the Panorama Prenatal Microdeletion Panel that is completed in conjunction with the Panorama Prenatal Screen when requested on the requisition form. I have discussed the reliability of test results and the level of certainty that a high risk test result for a certain disease serves as a predictor of such disease with my health care provider. I have had the opportunity to ask questions of my health care provider regarding this test, including the reliability of test results, the risks, and the alternatives prior to my informed consent. I request and authorize Natera to test my sample(s) for the above listed chromosome conditions and microdeletion syndromes. I understand that I must also sign this consent form, which will remain in my clinic chart.

I understand and hereby consent to the following processing activities with respect to the samples and related information I provide (Please check the applicable box(es) below):

☐ My samples and related information will be sent to a facility of Natera (as Data Processor) outside of the EU for performance of the test(s) ordered. (**Your consent is required in order for Data Processor to perform the ordered test(s).)**

☐ Data Processor may keep leftover samples and related information for future research & development, validation and quality assurance purposes, either independently or in collaboration with third-party partners; I and my heirs will not receive any payments, benefits, or rights to any resulting products or discoveries from the samples provided.

* If you do not consent to the use of your samples for future research & development, then your samples will be destroyed within 60 days after the performance of the ordered test. If you consent to the use of your leftover samples for future research & development, then leftover samples will be kept by Data Processor in compliance with applicable laws, including the GDPR.

_____

Signature of Patient Date

_____

Printed Name